ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition

Reuters

2025/10/01

ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition

ESSA Pharma Inc. announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87304) on September 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572374883"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572374883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572374883?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572374883","market":"fut","top_or_hot":-1,"title":"ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87304) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-01 04:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87304) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLc7ZtpV:1","article_id":"2572374883","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572374883","pubTimestamp":1759264298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the ori","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EPIX":"ESSA Pharma Inc."},"translate_title":"ESSA Pharma提供有关XenoTherapeutics收购特别会议和法院批准的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPIX":0.9},"content_text":"ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition\n    \n\nESSA Pharma Inc. announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87304) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}